Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
David Olmos(Royal Marsden NHS Foundation Trust), Sophie Postel‐Vinay(Royal Marsden NHS Foundation Trust), L Rhoda Molife(Royal Marsden NHS Foundation Trust), Scott H. Okuno(Mayo Clinic in Arizona), Scott M. Schuetze(University of Michigan), M. Luisa Paccagnella(Pfizer (United States)), Gretchen N. Batzel(Mayo Clinic in Arizona), Donghua Yin(Pfizer (United States)), Kathy Pritchard‐Jones(Royal Marsden NHS Foundation Trust), Ian Judson(Royal Marsden NHS Foundation Trust), Francis P. Worden(University of Michigan), Antonio Gualberto(Pfizer (United States)), Michelle Scurr(Royal Marsden NHS Foundation Trust), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Paul Haluska(Mayo Clinic in Arizona)
Cited by 338Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis